IQVHealthcare · Diagnostics & ResearchThe 21 Wall Street analysts covering IQVIA Holdings, Inc. hold a median 12-month price target of $278 — +17.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IQVIA Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (66): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IQV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +17.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Baird | Maintains | Outperform | $252 → $287 |
| 29 July 2026 | BMO Capital | Maintains | Outperform | $210 → $270 |
| 29 July 2026 | JP Morgan | Maintains | Overweight | $225 → $285 |
| 29 July 2026 | RBC Capital | Maintains | Outperform | $221 → $247 |
| 29 July 2026 | Stifel | Maintains | Buy | $220 → $276 |
| 29 July 2026 | TD Cowen | Maintains | Buy | $233 → $288 |
| 13 July 2026 | Mizuho | Maintains | Outperform | $215 → $230 |
| 13 July 2026 | Mizuho | Maintains | Outperform | — |
| 1 July 2026 | Baird | Maintains | Outperform | — |
| 17 June 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 9 Mar 2026 | TD Cowen | Upgrade | Buy | — |
| 6 Mar 2026 | Barclays | Upgrade | Overweight | — |
| 3 Mar 2026 | RBC Capital | Initiates | Outperform | — |
| 19 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 6 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 6 Feb 2026 | Jefferies | Maintains | Buy | — |
| 6 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Feb 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IQV appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 50% of US stocks
Cheaper than 17% of US stocks
Cheaper than 19% of US stocks
Higher than 49% of US stocks
Higher than 31% of US stocks
Higher than 39% of US stocks
Higher than 69% of US stocks
Higher than 66% of US stocks
Higher than 84% of US stocks
Higher than 76% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IQVIA Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IQVIA Holdings shares rose 41.5% over three months, driven by record R&D services bookings, a strong backlog, raised 2026 guidance, and ongoing share buybacks.
Why it matters — An IQV watcher would care because the stock's recent surge reflects improved confidence in the company's growth trajectory and financial outlook.
Zacks Investment Research highlights IQVIA Holdings as a top value stock for the long term. The piece references the Zacks Style Scores feature of the Zacks Premium research service, which helps investors identify strong stocks across value, growth, or momentum styles.
Why it matters — The item positions IQVIA favorably as a long-term value stock per Zacks' research framework, which could inform how IQVIA watchers assess its investment profile.
Zacks Investment Research highlighted IQVIA Holdings as a top-ranked momentum stock, noting that investors can use Zacks Style Scores to identify strong stocks across value, growth, and momentum categories.
Why it matters — IQV watchers would care because the stock is being singled out for a strong momentum ranking by a prominent research service.
Zacks notes IQVIA's proprietary data platform and expanding clinical research business support growth, while high leverage and liquidity risks keep the investment outlook balanced. The item frames IQV's prospects as a mix of growth drivers and persistent debt-related concerns.
Why it matters — An IQV watcher would care because the item weighs the company's growth engines against its ongoing debt and liquidity risks, which bear directly on its investment case.
IQVIA shares jumped 13% in a week after the company reported a second-quarter earnings beat, record bookings, and raised its 2026 guidance. Whether the gains last depends on execution and how well the company converts its backlog.
Why it matters — A watcher of IQVIA would care because the share-price move was driven by a beat, record bookings, and higher guidance, but sustainability depends on future execution and backlog conversion.
The 21 Wall Street analysts covering IQVIA Holdings, Inc. have a median 12-month price target of $278, with estimates ranging from $240 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering IQVIA Holdings, Inc., 19 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IQVIA Holdings, Inc. 92 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, IQVIA Holdings, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +17.5% from the last close, and Ticker Nerd's factor model ranks IQVIA Holdings, Inc. 92 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IQVIA Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IQV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $240 to $300 over the next 12 months.
IQVIA Holdings, Inc. returned +25.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
The most recent item we track (Zacks Investment Research, 12 Aug 2026): "IQV Stock Gains 42% in 3 Months: Here's What You Should Know". IQVIA Holdings shares rose 41.5% over three months, driven by record R&D services bookings, a strong backlog, raised 2026 guidance, and ongoing share buybacks.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company supports pharmaceutical, biotechnology, medical device, and healthcare organizations in developing, testing, and commercializing therapies using extensive real-world data, predictive analytics, and technology platforms. Its Technology and Analytics Solutions segment delivers healthcare data, decision-support tools, and software to clients such as manufacturers, providers, payers, and policymakers, helping them optimize clinical and commercial performance. The Research and Development Solutions segment focuses on outsourced clinical trial services, including late-stage and virtual clinical trials for drugs, devices, and diagnostics. IQVIA also offers contract sales and medical solutions that assist with commercialization and field-based engagement. Founded in 1950 and headquartered in Durham, North Carolina, IQVIA plays a central role in the healthcare ecosystem by enabling more efficient evidence generation, regulatory submissions, and market access strategies across more than 100 countries worldwide.
CEO Mr. Ari Bousbib · 94,000 employees · United States · https://www.iqvia.com